GLP1R and atherosclerosis: Our group previously reported that the subcutaneous infusion of human native glucagon-like peptide-1 (GLP-1) suppressed the development of atherosclerotic lesions in apolipoprotein E-null (Apoe−/−) mice, a representative animal model of atherosclerosis [4].